ORLANDO — A novel triple-agent combination of carfilzomib, dexamethasone and daratumumab outperformed carfilzomib plus dexamethasone in terms of PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to results of the randomized phase 3 CANDOR trial presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.The
Institutional peer review led to recommended changes in more than one-quarter of radiotherapy treatment plans, according to results of a systematic review and meta-analysis.Recommendations for…
SAN DIEGO — Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically significant exacerbations, according to a poster…
Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and phentermine/topiramate, but their estimated net price is too high for them to be…
SAN DIEGO — Patients have twice the risk of inpatient complications and mortality after having a second, contralateral hip fracture within 5 years of their…
Adults with type 1 diabetes who initiated treatment with a bionic pancreas at a primary care site experienced similar glycemic benefits as those starting the…
Short sleep duration, with and without self-reported insomnia, was predictive of elevated blood pressure and hypertension among adolescents, a speaker reported.At the American Heart Association’s…
Researchers at St. Jude Children’s Research Hospital identified a panel of 27 serum proteins that accurately predicted cardiomyopathy risk among childhood cancer survivors treated with…
Jobs with high IPF mortality ratios differed by sex, but notable categories for both included the public administration industry and health care practitioners and technical…
SAN FRANCISCO — New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly injections already…
Poor physical function correlated with outcomes among patients with non-Hodgkin lymphoma who underwent chimeric antigen receptor T-cell therapy, according to results of a retrospective cohort…
